Samus Therapeutics Presents Phase 1 PU-AD Study Results at AAIC 2020 Advancing the Company’s Platform for Treating Neurodegenerative Diseases
Excerpt from the Press Release:
BOSTON, July 29, 2020 /PRNewswire/ — Samus Therapeutics, Inc., a privately held, biopharmaceutical company developing small molecule epichaperome inhibitors , today announced the presentation of safety and pharmacokinetic data from the Company’s recently completed PU-AD healthy volunteer Phase 1 study at the Alzheimer’s Association International Conference (AAIC 2020). PU-AD is Samus’ orally bioavailable, small molecule epichaperome inhibitor designed to cause degradation of aberrant proteins associated with the progression of Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and other major neurodegenerative diseases. The Phase 1 study results presented today support Samus’ advancement of PU-AD into its now initiated Phase 2a study in AD, and its upcoming Phase 2a study in ALS expected to initiate later this year.
Click the button below to read the Press Release:
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?